Antimicrobial therapy for acute colonic diverticulitis

Surgical Infections

Volumn 10, Issue 2, 2009, Pages 143-154

  Byrnes, Matthew C ^a   Mazuski, John E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG;

ALLERGIC REACTION; ANAEROBIC BACTERIUM; ANAPHYLAXIS; ANTIMICROBIAL THERAPY; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; COLON DIVERTICULOSIS; DRUG USE; ENTEROCOCCUS; FUNGUS; GRAM NEGATIVE BACTERIUM; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IN VITRO STUDY; MEDICAL LITERATURE; MEDLINE; MICROBIOLOGY; OUTPATIENT CARE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION;

ACUTE DISEASE; ANTI-INFECTIVE AGENTS; DIVERTICULITIS, COLONIC; HUMANS;

EID: 66249113892     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2007.087     Document Type: Review

References (73)

1. Ferzoco LB, Raptopoulos V, Silen W, Acute diverticulitis. N Engl J Med 1998 338: 1521-1526.
2. Rafferty J, Shellito P, Hyman NH, Buie WD. Practice parameters for sigmoid diverticulitis. Dis Colon Rectum 2006;49:939-944.
3. Stollman NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999;94:3110-3121.
4. Dominguez EP, Sweeney JF, Choi YU. Diagnosis and management of diverticulitis and appendicitis. Gastroenterol Clin North Am 2006;35: 367-391.
5. Kang JY, Melville D, Maxwell JD. Epidemiology and management of diverticular disease of the colon. Drugs Aging 2004;21: 211-228.
6. Mueller MH, Glatzle J, Kasparek MS, et al. Long-term outcome of conservative treatment in patients with diverticulitis of the sigmoid colon. Eur J Gastroenterol Hepatol 2005;17:649-654.
7. Arfwidsson S, Knock NG, Lehmann L Winberg T. Pathogenesis of multiple diverticula of the sigmoid colon in diverticular disease. Acta Chir Scand Suppl 1964 63(Suppl 342):l-68.
8. Painter NS. Diverticulosis of the colon and diet. Br Med J 1969;2:764-765.
9. Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol 1975;4:53-69.
10. Kaiser AM, Jiang JK, Lake JP, et al. The management of complicated diverticulitis and the role of computed tomography. Am J Gastroenterol 2005;100:910-917.
11. Fleischner FG, Ming SC. Revised concepts on diverticular disease of the colon II: So-called diverticulitis: Diverticular sigmoiditis and persigmoiditis; diverticular abscess, fistula, and frank peritonitis. Radiology 1965;84:599-609.
12. Stollman N, Raskin JB. Diverticular disease of the colon. Lancet 2004;363:631-639.
13. Buchanan GN, Kenefick NJ, Cohen CR. Diverticulitis. Best Pract Res Clin Gastroenterol 2002;16:635-647.
14. Hinchey EJ, Schaal PG, Richards GK. Treatment of perforated diverticular disease of the colon. Adv Surg 1978;12:85-109.
15. Chang GJ, Shelton AA, Welton ML. Large intestine. In: Doherty GM, Way LW, editors. Current Surgical Diagnosis & Treatment. 12th edition. New York. McGraw Hill, 2006. Pp.685-737.
16. Christou NV, Turgeon P, Wassef R, et al. Management of intra-abdominal infections: The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group. Arch Surg 1996;131:1193-1201.
17. Brook I, Frazier EH. Aerobic and anaerobic microbiology of retroperitoneal abscesses. Clin Infect Dis 1998;26:938-941.
18. Brook I, Frazier EH. Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. J Med Microbiol 2000;49:827-830.
19. Solornkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005.
20. Hjern F, Josephson T, Altman D, et al. Conservative treatment of acute colonic diverticulitis: Are antibiotics always mandatory? Scand J Gastroenterol 2007;42:41-47.
21. Kellum JM, Sugerman HJ, Coppa GF, et al. Randomized, prospective comparison of cefoxitin and gentamicin-clin-damycin in the treatment of acute colonic diverticulitis. Clin Ther 1992;14:376-384.
22. Onderdonk AB, Bartlett JG, Louie T, et al. Microbial synergy in experimental intra-abdominal abscess. Infect Immun 1976;13:22-26.
23. Yellin AE, Heseltine PN, Berne TV, et al. The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985;161:303-307.
24. Falagas ME, Barefoot L, Griffith J, et al. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996;15:913-921.
25. Wong WD, Wexner SD, Lowry A, et al. Practice parameters for the treatment of sigmoid diverticulitis-Supporting documentation. The Standards Task Force, The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 2000;43:290-297.
26. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect 2002;3:161-173.
27. 27. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med 1996;124:717-725. (Pubitemid 126495163)
28. Study Group of Intraabdominal Infections. A randomized controlled trial of ampicillin plus sulbactam vs. gentamicin plus clindamycin in the treatment of intraabdominal infections: A preliminary report. Rev Infect Dis 1986;8(Suppl 5):S583-S588.
29. Schropp KP, Kaplan S, Golladay ES, et al. A randomized clinical trial of ampicillin, gentamicin and clindamycin versus cefotaxime and clindamycin in children with ruptured appendicitis. Surg Gynecol Obstet 1991;172:351-356.
30. Williams RR, Hotchkin D. Aztreonam plus clindamycin versus tobramycin plus clindamycin in the treatment of intraabdominal infections. Rev Infect Dis 1991;13(Suppl 7):S629-S633.
31. Eckhauser FE, Knol JA, Raper SE, et al. Efficacy of two comparative antibiotic regimens in the treatment of serious intra-abdominal infections: Results of a multicenter study. Clin Ther 1992;14:97-109.
32. Bailey JA, Virgo KS, DiPiro JT, et al. Aminoglycosides for intra-abdominal infection: Equal to the challenge? Surg Infect 2002;3:315-335.
33. Mazuski JE, Sawyer, RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: Evidence for the recommendations. Surg Infect 2002;3:175-233.
34. Malangoni MA, Condon RE, Spiegel CA. Treatment of intra-abdominal infections is appropriate with single-agent or combination antibiotic therapy. Surgery 1985;98:648-655.
35. Hopkins JA, Wilson SE, Bobey DG. Adjunctive antimicrobial therapy for complicated appendicitis: Bacterial overkill by combination therapy. World J Surg 1994;18:933-938.
36. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Arch Surg 1997;132:1294-1302.
37. Berne TV, Yellin AE, Appleman MD, et al. A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. Surg Gynecol Obstet 1993;177(Suppl):18-22.
38. Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 1993;217:115-121.
39. Chow JW, Satishchandran V, Snyder TA, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect 2005;6:439-448.
40. Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004;23:682-687.
41. Dougherty SH, Sirinek KR, Schauer PR, et al. Ticarcillin/ clavulanate compared with clindamycin/gentamicin (with or without arnpicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. Am Surg 1995;61:297-303.
42. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-2773.
43. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000;232:254-262.
44. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: Results of a double-blind, randomized comparative phase III trial. Ann Surg 2003;237:235-245.
45. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995;35:139-148.
46. Donahue PE, Smith DL, Yellin AE, et al. Trovafloxacin in the treatment of intra-abdominal infections: Results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group. Am J Surg 1998;176(6A Suppl):53S-61S.
47. Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerabil-ity of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized double-blind noninferiority study. Clin Ther, 2008;30:868-883.
48. Elsakr R, Johnson DA, Younes Z, Oldfield EC III. Antimicrobial treatment of intra-abdominal infections. Dig Dis 1998;16:47-60.
49. Barboza E, del Castillo M, Yi A, Gotuzzo E. Clindamycin plus amikacin versus clindamycin plus aztreonam in established intraabdominal infections. Surgery 1994;116:28-35.
50. Gordon KA, Jones RN, SENTRY Participant Groups (Europe, Latin America, North America). Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: Comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2003;45:295-301.
51. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 2005;41(Suppl 5):S354-S367.
52. Solornkin IS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/ oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-abdominal Infection Study Group. Ann Surg 1996;223:303-315.
53. Yoshioka K, Youngs DJ, Keighley MR. A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection. Infection 1991;19:25-29.
54. Hoogkamp-Korstanje JA. Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections. Infection 1995;23:278-282.
55. Malangoni MA, Song J, Herrington J, et al. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006;244:204-211.
56. Wirtz M, Kleeff J, Swoboda S, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004;53:875-877.
57. Moxifloxacin (Avelox) [package insert]. West Haven, Connecticut: Bayer Pharmaceuticals Corporation, 2007.
58. Drudy D, Quinn T, O'Mahony R, et al. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 2006;58:1264-1267.
59. Carroll DN. Moxifloxacin-induced Clostridium difficile-associated diarrhea. Pharmacotherapy 2003;23:1517-1519.
60. Ackermann G, Tang-Feldman YJ, Schaumann R, et al. Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clin Microbiol Infect 2003;9:526-530.
61. Ortiz-de-Saracho J, Pantoja L, Romero MJ, Lopez R. Moxifloxacin-induced Clostridium difficile diarrhea. Ann Pharma-cother 2003;37:452-453.
62. Owens RC Jr, Kruesmann F, Reiter C, et al. Comparative frequency of Clostridium difficile-associated diarrhea in phase II and phase III moxifloxacin clinical trials. Presented at the 7th European Congress of Chemotherapy and Infection, Florence, Italy, October 19-22, 2005.
63. Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 2007;45:222-227.
64. Weiss K, Bergeron L, Bernatchez H, et al. Clostridium difficile-associated diarrhoea rates and global antibiotic consumption in five Quebec institutions from 2001 to 2004. Int J Antimicrob Agents 2007;30:309-314.
65. Cuchural GJ Jr, Tally FP, Jacobus NV, et al. Susceptibility of the Bacteroides fragilis group in the United States: Analysis by site of isolation. Antimicrob Agents Chemother 1988;32:717-722.
66. Aldridge KE, O'Brien M. In vitro susceptibilities of the Bacteroides fragilis group species: Change in isolation rates significantly affects overall susceptibility data. J Clin Microbiol 2002;40:4349-4352
67. Klevens RM, Morrison MA, Nadle J, et al. Invasive rnethi-cillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-1771.
68. Mazuski JE. Clinical challenges and unmet needs in the management of complicated intra-abdominal infections. Surg Infect 2005;6:S49-S69.
69. Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486-494.
70. Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of enterococcus in intra-abdominal infection: Analysis of a prospective randomized trial. Surgery 1995;118:716-721.
71. Harbarth S, Uckay I. Are there patients with peritonitis who require empiric therapy for Enterococcus? Eur J Clin Microbiol Infect Dis 2004;23:73-77.
72. Calandra T, Bille J, Schneider R, et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989;2:1437-1440.
73. Smith JA, Bell GA, Murphy J, et al. Evaluation of the use of a protocol in the antimicrobial treatment of intra-abdominal sepsis. J Hosp Infect 1985;6:60-64.